[Modifications of markers of bone resorption in patients affected by glucocorticoid induced osteoporosis (GIOP) treated with neridronate].
Almost 30-50% of patients on long-term therapy with glucocorticoids (GC), especially those affected by rheumatic diseases, develop glucocorticoid induced osteoporosis (GIOP) and osteoporosis-related fractures. To assess the effects of neridronate versus placebo on markers of bone resorption in rheumatic patients affected by GIOP (as defined by a T Score reduction > 2.5; mean BMD L2-L4), sixty-two female patients [age: 68.89 +/- 9.45 (mean +/- SD)] affected by different rheumatic diseases, like rheumatoid arthritis, polymyalgia rheumatica, Sjögren syndrome in treatment with a mean prednisone-equivalent daily dose of 6.44 +/- 2.4 mg/day, were enrolled in an open trial. The patients were divided in 2 groups: group A (26 patients) assuming daily calcium 1 g and vitamin D 800 UI and group B (36 patients) assuming daily calcium (1000 mg) and vitamin D (800 UI) and neridronate (25 mg im /30 days). The patients were evaluated for serum and urinary bone markers, basely (T0) and after 6 months of therapy (T6). After 6 months of therapy (T6), bone markers were significantly reduced in group B in respect to group A: OHPr - 41.64% (p < 0.001), D-Pyr - 34.96% (p < 0.001), NTX - 50.9% (p < 0.001). These preliminary data show that neridronate may be considered an useful agent for the treatment of GIOP in rheumatic patients.
Benucci
Maurizio
M
Sezione di Reumatologia, Dipartimento Medicina Interna, Nuovo Ospedale S.Giovanni di Dio, ASL 10, Firenze. maubenucci@tiscali.it
Dolenti
Stefano
S
Saviola
Gianantonio
G
Manfredi
Mariangela
M
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001862:Bone Resorption / Q000175:diagnosis / Q000188:drug therapy*; D002118:Calcium / Q000008:administration & dosage; D003627:Data Interpretation, Statistical; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy*; D011111:Polymyalgia Rheumatica / Q000188:drug therapy; D012859:Sjogren's Syndrome / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome; D014807:Vitamin D / Q000008:administration & dosage
D004164:Diphosphonates; D005938:Glucocorticoids; D014807:Vitamin D; C053389:6-amino-1-hydroxyhexane-1,1-diphosphonate; D002118:Calcium